(TEAR, BLRX, PLCM) CRWENewswire Stocks In Action
BioLineRx Ltd -BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. On its Fourth quarter fiscal 2011, Polycom Inc - PLCM - posted record consolidated net revenues of $407 million, compared to $340 million in the same period the prior year. and lastly; TearLab Corp - TEAR - reported that after reviewing and accepting labeling submitted to it by the Company, the FDA has now granted Waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 for the TearLab Osmolarity System.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

ユーザー：karmastock
再生時間：00:01:15
投稿日時：12/01/25 4:39
カテゴリ：ビジネス全般 
タグ： PLCM  TEAR  BLRX  Nasdaq:BLRX  Nasdaq:TEAR  Nasdaq:PLCM 

[ 前ページへ戻る ]